Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 12/20 | 0.35 |
| ▸ | AKT1 | P31749 | 5/20 | 0.35 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083214 | 0.84 | HCAR2 (0.36) | RPS6KB1AKT1CSNK2A2CSNK2B | |
| SCHEMBL3120919 | 0.83 | — | — | |
| SCHEMBL1689336 | 0.72 | CCNA2 (0.42) | CCNA2CDK2CCNA1PDPK1RPS6KB1 | |
| SCHEMBL1559614 | 0.72 | CCNA2 (0.52) | CCNA2CDK2CCNA1PDPK1RPS6KB1 | |
| SCHEMBL14763163 | 0.72 | CDK9 (0.36) | CCNA2CDK2 | |
| SCHEMBL10726068 | 0.72 | PIM1 (0.31) | — | |
| SCHEMBL3117771 | 0.72 | PIM1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL1560040 | 0.71 | CCNA2 (0.51) | CCNA2CDK2CCNA1PDPK1RPS6KB1 | |
| SCHEMBL3985165 | 0.69 | MAP2 (0.46) | CCNA2CDK2CCNA1PDPK1ADORA3 | |
| SCHEMBL5084942 | 0.69 | RPS6KB1 (0.38) | CCNA2CDK2CCNA1RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689752-A1 | PYRAZOLOPYRIMIDINES | Pfizer Limited (GB) | 2006-08-16 | — | — | EP | claimed |
| WO-2005049617-A1 | PYRAZOLOPYRIMIDINES | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| EP-2911672-A1 | USE OF A TETRASUBSTITUTED PYRAZOLO[4,3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY | Pfizer Inc. (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014064566-A1 | USE OF A TETRASUBSTITUTED PYRAZOLO[4,3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY | PFIZER INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2008132589-A1 | COMBINATIONS COMPRISING PREGABALIN | PFIZER LIMITED (GB) | 2008-11-06 | — | — | WO | disclosed |